Incyte Has Six Phase III Assets. It Just Admitted One Doesn't Count.

A CDK2 retreat, a guidance raise, and a date with ASH — the quarter Incyte finally ranked its own pipeline out loud.

INCY · Earnings Call · 2026-10-29

The pruning, said out loud

For a year Bill Meury has sold the same idea in different clothes: Incyte is no longer a Jakafi company with a pipeline attached, it is a pipeline company with a Jakafi cash machine attached. This quarter he attached a footnote. One of the six Phase III assets is being walked back, and management said so on the record rather than burying it. On the CDK2 inhibitor, 667, Pablo Cagnoni was blunt about platinum-resistant ovarian cancer: “the study would be very challenging to accrue, and number two, the commercial prospects in that indication were limited” — Pablo Cagnoni, President, Head of Research & Development · 2026-10-29. The randomized Phase III MAESTRA-2 stops enrolling; the maintenance study continues. The CDK2 inhibitor simply isn't getting any more sites. What makes that worth a paragraph isn't the asset — it's the candor of the ranking that followed. Asked to level-set the pipeline, Meury graded it live: “Povorcitinib, 989, 12D, and latarcibart are comparatively higher PTRS projects... CDK2, the last one, I would describe as an incremental opportunity” — Bill Meury, Chief Executive Officer · 2026-10-29. That is a CEO telling you the "six Phase III assets" number is a headcount, not a portfolio. The callback is almost too tidy. In July, explaining capital allocation, Meury said the quiet part: if the facts change or performance disappoints,

if any of the investments that we're making, if the facts and circumstances around those investments change or performance is not what we expected, we stop making those investments
William Meury, Chief Executive Officer · 2026-07-28

. Three months later, that sentence has a name. Note also that on the July call the same 667 program was being framed as a win — “we also think it's an important update, derisking the maintenance study that we're conducting in that program” — Pablo Cagnoni, President, Head of R&D · 2026-07-28. Derisking became de-prioritizing in one quarter, and credit is due for saying it plainly.

The core is doing exactly what it promised

Against that, the commercial quarter was clean. Total revenue of $1.56 billion, up 14%; total net sales $1.32 billion, up 14%; and the number that actually matters for the 2029 transition — core ex-Jakafi net sales of $490 million, up 30%. OPZELURA did $255 million, +36% reported and +21% pro forma once you strip the Medicaid line-extension settlement out of the base. Guidance went up across the board: total net sales to $5.210–5.300 billion, OPZELURA to $1.1–1.12 billion, hematology and oncology to $890–910 million. Mohamed Issa gave the cleanest read on why the franchise is durable rather than just discounted: “new patient volume, which is really the best measure of competitiveness, grew 2x market” — Mohamed Issa, Executive Vice President, U.S. Commercial · 2026-10-29, which is a far better signal than any gross-to-net conversation. And the European approval of OPZELURA in moderate atopic dermatitis makes it the first steroid-free topical JAK inhibitor in that market — a genuine white space, not a me-too. Jakafi itself did $827 million, +4%, with 12% underlying demand outrunning price drag from the CMS model. XR is tracking toward roughly $50 million for the year with formulary coverage above 80% by year-end, and management still targets retaining 10–30% of the franchise into 2029. Here's the valuation context that makes the whole argument worth having. Incyte trades at 3.9x revenue, down 88% from the 32.4x it commanded in 2015. The market has already decided Jakafi is a melting ice cube. Everything above is an argument about the price of the ice and the credibility of what replaces it.

ASH is the binary

The asset carrying the most weight is 989, the mutant CALR antibody. Roughly 55 frontline patients will be presented at ASH — about 20 JAK-ineligible (the EHA cohort) and roughly 40 genuinely treatment-naive — split two-thirds monotherapy, one-third combination with ruxolitinib. Cagnoni pre-emptively warned against the abstract: “the data in the abstract are much more immature than the data in the presentation” — Pablo Cagnoni, President, Head of Research & Development · 2026-10-29, with the presentation cut about four months later. Read that as a hedge in both directions. Underneath sits a regulatory swing most investors underweight: a Type C meeting with the FDA's surrogate endpoints team to shift the frontline discussion away from SVR35 and TSS50 toward a composite endpoint capturing hemoglobin, platelets, blasts and spleen. If that lands, 989 is a disease-modifying franchise. If it doesn't, Incyte is running a conventional myelofibrosis trial against an entrenched incumbent. The same logic applies to povorcitinib's hidradenitis label — Meury is explicitly planning for both a pre- and post-biologic broad label, which is the honest way to describe a range of outcomes you don't control.

The Vega bill and the accounting fog

GAAP operating expenses rose 146% and R&D rose 254%, which sounds alarming until you find the $1.23 billion IPR&D charge for the Vega acquisition — roughly $1.27 billion of total cash consideration for latarcibart, the Protein S modulator in von Willebrand disease. Strip it out and, per Suky Upadhyay, “total operating expenses for the quarter grew 12%” — Suky Upadhyay, Chief Financial Officer · 2026-10-29. That's the honest operating number. But there's a subtler point in the underlying trend. Quarterly R&D of $517 million is only modestly above last year and well below the $654 million peak set in early 2025. Against Q2 revenue of $1.674 billion, that puts R&D at roughly 31% of revenue. Meury's insistence that the company is "fully funding and resourcing" its Phase III programs is true in spirit but not in the slope of the line. The discretionary pruning of CDK2 is what makes both statements compatible. The balance sheet — $3.9 billion in cash — is what lets Incyte buy its way past the 2029 cliff, which is exactly what the Vega deal was.

What this report actually is

This is not a company riding a market wave. The global theme tape for the last month is dominated by data centers, bitcoin miners and power — nothing Incyte touches. The clinical-trial vocabulary that shows up globally (open label extension-style milestones, DAWN 302-adjacent oncology readouts at peers like Astellas and GSK) confirms a sector backdrop, not a shared narrative. This is a company-specific story. And the keyword shift inside Incyte tells it well: last quarter's list was dominated by broad framing — late stage, von Willebrand, Type 1 patients. This quarter's list is specific: DAWN 302, CALR antibody, SUNLIGHT study, ovarian cancer, wild type versus mutated cells. The story got narrower and more falsifiable, which is usually what happens right before a binary readout. The stock has softened into the print: +7.7% over 90 days but 10.1% below its late-July peak of $129.93. The market is not paying for the pipeline yet. It is waiting for ASH, for the povorcitinib label, and for the FDA to decide whether a composite endpoint can replace a spleen volume. If any one of those three goes the right way, a 3.9x revenue multiple on a company with $5.3 billion of guided sales and $3.9 billion of cash starts to look like the mispricing rather than the verdict.